Size | Price | Stock | Qty |
---|---|---|---|
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
10g |
|
||
Other Sizes |
|
Purity: ≥98%
Targets |
CRBN; TNF-α (IC50 = 13 nM)
|
---|---|
ln Vitro |
(magnification, ×200).Pomalidomide has an IC50 of 13 nM and a 25 nM, respectively, for inhibiting lipopolysaccharide (LPS) stimulated TNF-alpha release in human PBMC and human whole blood. [1] Pomalidomide has an IC50 of 1 μM and inhibits T regulatory cell growth that is induced by IL-2. [2] Pomalidomide (6.4 nM–10 M) treatment causes an increase in IL-2 production in human peripheral blood T cells; this effect is marginally more pronounced in the CD4+ subset than in the CD8+ subset. Pomalidomide has a much greater ability to increase IL-2, IL-5, and IL-10 levels than CC-5013, but it has only a marginally greater ability to increase IFN-γ levels. Pomalidomide enhances SEE and Raji cells induced AP-1 transcriptional activity in Jurkat cells in a dose-dependent manner, with a maximal enhancement of 4-fold at 1 μM. [3] When Raji cells are exposed to different Pomalidomide concentrations (2.5–40 μg/mL) for 48 hours, cell proliferation and DNA synthesis are significantly reduced. In comparison to controls treated with the vehicle, there is a 40% reduction. [4]
|
ln Vivo |
In mice with severe combined immunodeficiency, pomalidomide improves rituximab's ability to treat B-cell lymphomas. In contrast to the 58 days of CC5013/rituximab treatment and the 45 days of rituximab nonotherapy, the mice with the combination of pomalidomide and rituximab have a median survival period of 74 days. Pomalidomide and rituximab have a synergistic effect, but this effect can be completely reversed by NK cell depletion, which lends support to the idea that one way Pomalidomide may increase rituximab antitumor activity is by promoting NK cell expansion. [4]
|
Enzyme Assay |
TNF-α inhibitory activity is measured in lipopolysacharide (LPS) stimulated PBMC. Pomalidomide is added to human PBMCs one hour before LPS (1 μg/mL) is added, and incubation is then continued for an additional 18 to 20 hours.
The concentration of TNF-α is then measured in the supernatants using an ELISA after they are harvested. Nonlinear regression analysis is used to determine the amount of pomalidomide (IC50) required to reduce TNF-production by 50%. Similar to the PBMC assay, the human whole blood TNF-inhibition assay is carried out except that fresh human whole blood that has been heparinized is directly plated onto microtiter plates.
|
Cell Assay |
Pomalidomide (5 μg/mL) is applied to Lymphoma cell lines for 24 or 48 hours in order to measure cell apoptosis. Propidium iodine and FITC-labeled Annexin V are used to stain the cells. Fluorescence-activated cell sorter/FACStar Plus flow cytometer multicolor flow cytometric analysis is used to examine cell apoptosis. When cells show signs of early or late apoptosis (Annexin V positivity and propidium iodine negativity or positivity, respectively), they are considered to be apoptotic. The Lymphoma cell lines are exposed to Pomalidomide (2.5, 5, 10, 20, and 40 μg/mL) for 24 or 48 hours to measure cell proliferation. After adding 1 μCi of [3H]-thymidine per well (in a 96-well plate), the cells are given another 18 hours of incubation. The [3H]-thymidine uptake is then determined using an automated scintillation counter after cells are harvested using the Harvest system and placed into 96-well glass filters.
|
Animal Protocol |
Mice: SCID mice aged six to eight weeks are used for this. All of the animals are injected with 1×106 Raji cells through their tail veins on day 0. The animals are divided into seven cohorts following 72 hours of tumor engraftment. The first cohort (group A) serves as the control and is not given any medication. Animals in Groups B and C were given either CC-5013 (0.5 mg/kg) or Pomalidomide (0.5 mg/kg) intravenously on Days +3, +4, +8, +9, +13, +14, +18, and +19. Rituximab or Trastuzumab (isotype control) monotherapy is administered to Groups D and E on Days +5, +10, +15, and +20 by tail vein injection at a dose of 10 mg/kg. Animals treated with Rituximab and CC-5013 (group E) or Pomalidomide (group G) make up groups F and G, respectively. Prior to each dose of Rituximab, IMiDs are administered intravenously for two consecutive days. Animals are monitored for 90 days after therapy is over. The study's primary outcome is survival, which is measured as the amount of time before limb paralysis sets in. Cervical dislocation is used to kill any animals that reach the end point or remain alive after three months of observation. To find any remaining disease, a pathologic examination of all organs is conducted, including the liver, lungs, and brain. Three different times, the experiments are repeated.
Rats: Three male CD-IGS rats in total are used. Pomalidomide is given as a single PO administration through the stomach cannula at a dose of 50 mg/kg (5 mL/kg) in a suspension formulation of 0.5% carboxymethylcellulose/0.25% Tween 80. Ten hours after dosing, microdialysate is collected in a cooling fraction collector set to 4°C at intervals of 25 minutes. Each sample's corrected concentration is multiplied by the sampling interval, in this case 25 minutes, and divided by the number of hours in a day to obtain the AUC. These values added together represented the overall AUC value for the given time frame. The concentration is plotted at each time point at the halfway point of each collection interval in order to create graphs. Within 12 hours of the specified time points, microdialysates are collected and analyzed for the presence of pomalidomide using a LC-MS/MS assay. |
References |
|
Molecular Formula |
C13H11N3O4
|
---|---|
Molecular Weight |
273.24
|
Exact Mass |
273.07496
|
Elemental Analysis |
C, 57.14; H, 4.06; N, 15.38; O, 23.42
|
CAS # |
19171-19-8
|
Related CAS # |
Pomalidomide-d3;2093128-28-8;Pomalidomide-d5;1377838-49-7;Pomalidomide-d4;1416575-78-4
|
Appearance |
white solid powder
|
SMILES |
C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N
|
InChi Key |
UVSMNLNDYGZFPF-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)
|
Chemical Name |
4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
|
Synonyms |
CC4047; CC-4047; CC 4047; Pomalidomide. Brand name: Pomalyst
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.15 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: 1% DMSO +30% polyethylene glycol+1% Tween 80 : 15mg/mL Solubility in Formulation 4: 10 mg/mL (36.60 mM) in 0.5% CMC-Na 0.5% Tween-80 (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.6598 mL | 18.2989 mL | 36.5979 mL | |
5 mM | 0.7320 mL | 3.6598 mL | 7.3196 mL | |
10 mM | 0.3660 mL | 1.8299 mL | 3.6598 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT03910244 | Active Recruiting |
Drug: Placebo oral capsule Drug: Pomalidomide Oral Product |
Telangiectasia, Hereditary Hemorrhagic |
The Cleveland Clinic | October 17, 2019 | Phase 2 |
NCT03257631 | Active Recruiting |
Drug: Pomalidomide | Central Nervous System Neoplasms Medulloblastoma |
Celgene | August 22, 2017 | Phase 2 |
NCT03113942 | Active Recruiting |
Drug: Pomalidomide 2 MG Oral Capsule [Pomalyst] |
High Grade Squamous Intra-epithelial Lesion (HSIL) |
Kirby Institute | June 14, 2017 | Phase 2 |
NCT02718833 | Active Recruiting |
Drug: Elotuzumab Drug: Pomalidomide |
Multiple Myeloma | Massachusetts General Hospital | June 2016 | Phase 2 |
NCT02400242 | Active Recruiting |
Drug: ACY-241 Drug: Pomalidomide |
Multiple Myeloma | Celgene | May 7, 2015 | Phase 1 |